NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
종목 코드 NGEN
회사 이름NervGen Pharma Corp
상장일Mar 13, 2019
CEORogers (Adam H)
직원 수- -
유형Ordinary Share
회계 연도 종료- -
주소Suite 1703 - 595 Burrard Street
도시VANCOUVER
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Canada
우편 번호V7X 1J1
전화16047225361
웹사이트https://www.nervgen.com/
종목 코드 NGEN
상장일Mar 13, 2019
CEORogers (Adam H)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음